These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 36569154)

  • 1. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.
    Shi M; Jakobsson V; Greifenstein L; Khong PL; Chen X; Baum RP; Zhang J
    Front Med (Lausanne); 2022; 9():1034315. PubMed ID: 36569154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M
    Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Humans Study of the SSTR Antagonist
    Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
    J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
    Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
    Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
    [No Abstract]   [Full Text] [Related]  

  • 6.
    King AP; Gutsche NT; Raju N; Fayn S; Baidoo KE; Bell MM; Olkowski CS; Swenson RE; Lin FI; Sadowski SM; Adler SS; Thiele NA; Wilson JJ; Choyke PL; Escorcia FE
    J Nucl Med; 2023 Apr; 64(4):549-554. PubMed ID: 36396453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant
    Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C
    J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893
    [No Abstract]   [Full Text] [Related]  

  • 8. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
    Adant S; Shah GM; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):907-921. PubMed ID: 31492995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.
    Kim K; Kim SJ
    Nucl Med Mol Imaging; 2018 Jun; 52(3):208-215. PubMed ID: 29942399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of [
    Simón M; Jørgensen JT; Khare HA; Christensen C; Nielsen CH; Kjaer A
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745856
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Rubira L; Deshayes E; Santoro L; Kotzki PO; Fersing C
    Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted
    Delpassand ES; Tworowska I; Esfandiari R; Torgue J; Hurt J; Shafie A; Núñez R
    J Nucl Med; 2022 Sep; 63(9):1326-1333. PubMed ID: 34992153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies.
    Ahmadi Bidakhvidi N; Goffin K; Dekervel J; Baete K; Nackaerts K; Clement P; Van Cutsem E; Verslype C; Deroose CM
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
    Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
    Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin Receptor Antagonists for Imaging and Therapy.
    Fani M; Nicolas GP; Wild D
    J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
    Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
    Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.
    di Santo G; Santo G; Sviridenko A; Virgolini I
    Theranostics; 2024; 14(3):940-953. PubMed ID: 38250038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.